Anzeige
Mehr »
Montag, 23.03.2026 - Börsentäglich über 12.000 News
Das "Next Butte?"-Setup in Montana - und es ist noch immer eine $15M-Story
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A41B4G | ISIN: CNE100006T02 | Ticker-Symbol: J8J
Frankfurt
20.03.26 | 15:25
7,100 Euro
-5,33 % -0,400
Branche
Biotechnologie
Aktienmarkt
ASIEN
1-Jahres-Chart
TRANSTHERA SCIENCES NANJING INC Chart 1 Jahr
5-Tage-Chart
TRANSTHERA SCIENCES NANJING INC 5-Tage-Chart

Aktuelle News zur TRANSTHERA SCIENCES Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DoTRANSTHERA-B (02617): DATE OF BOARD MEETING2
MiTRANSTHERA-B (02617): VOLUNTARY ANNOUNCEMENT FIRST PATIENT DOSED IN PHASE II CLINICAL TRIAL OF TINENGOTINIB IN COMBINATION WITH FULVESTRANT FOR THE TREATMENT ...1
09.03.TRANSTHERA-B (02617): VOLUNTARY ANNOUNCEMENT INCLUSION OF THE COMPANY AS A CONSTITUENT OF THE HANG SENG INDEX SERIES1
20.01.TRANSTHERA-B (02617): NEXT DAY DISCLOSURE RETURN1
20.01.TRANSTHERA-B (02617): COMPLETION OF PLACING OF NEW H SHARES UNDER THE GENERAL MANDATE2
13.01.TRANSTHERA-B (02617): PLACING OF NEW H SHARES UNDER GENERAL MANDATE5
12.01.TRANSTHERA-B (02617): VOLUNTARY ANNOUNCEMENT PRESENTATION OF CLINICAL DATA ANALYSIS OF TINENGOTINIB MONOTHERAPY IN PATIENTS WITH ADVANCED CHOLANGIOCARCINOMA ...1
TRANSTHERA SCIENCES Aktie jetzt für 0€ handeln
12.01.XFRA NEW INSTRUMENTS AVAILABLE ON 12.01.2026468The following instruments on XETRA do have their first trading 12.01.2026 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 12.01.2026 Aktien 1 CA2924833023 Enablence Technologies...
► Artikel lesen
19.12.25TransThera Sciences (Nanjing) Inc.: New Drug Application For Tinengotinib Tablets Accepted By The National Medical Products Administration178NANJING, China and GAITHERSBURG, Md., Dec. 18, 2025 /PRNewswire/ -- TransThera Sciences Nanjing, Inc. (the "TransThera") announced that the new drug application...
► Artikel lesen
19.12.25TRANSTHERA-B (02617): VOLUNTARY ANNOUNCEMENT NEW DRUG APPLICATION FOR TINENGOTINIB TABLETS ACCEPTED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION2
17.12.25TRANSTHERA-B (02617): VOLUNTARY ANNOUNCEMENT PUBLICATION OF CLINICAL RESULTS OF OUR CORE PRODUCT TINENGOTINIB AGAINST CHOLANGIOCARCINOMA-
03.12.25TRANSTHERA-B (02617): VOLUNTARY ANNOUNCEMENT INCLUSION OF TINENGOTINIB TABLETS IN THE LIST OF PRODUCTS FOR PRIORITY REVIEW BY THE NATIONAL MEDICAL PRODUCTS ...-
03.11.25Neurocrine pens $880M deal with China's TransThera for red-hot immunology target12
03.11.25TRANSTHERA-B (02617): VOLUNTARY ANNOUNCEMENT COLLABORATION WITH NEUROCRINE4
20.10.25TRANSTHERA-B (02617): INSIDE INFORMATION ANNOUNCEMENT PROPOSED IMPLEMENTATION OF THE H SHARE FULL CIRCULATION BY THE COMPANY1
25.09.25A wild ride for TransThera investors: what's the story?1
16 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1